[ad_1]
MyEG has announced that it has signed an exclusive agreement with Anhui Zhifei Longcom Biopharmaceutical Co Ltd (Zhifei) to obtain Malaysian Halal certification for the COVID-19 vaccine from the Chinese pharmaceutical company. The agreement also allows MyEG to secure a 3-year exclusivity to distribute the vaccine in Malaysia.
According to the official statement, both companies signed a memorandum of understanding and agreed to cooperate in conducting phase 3 clinical trials of Zhifei’s COVID-19 vaccine in Malaysia, as well as achieving compliance with Halal status requirements to ensure the Halal certification requirements from the Department of Islamic State. Development Malaysia (JAKIM). JAKIM’s Halal accreditation will ensure greater acceptance of the vaccine among the global Muslim population.
MyEG says the phase 3 trial will make Zhifei’s vaccine one of the first to undergo end-stage trials in Malaysia under the purview of the Ministry of Health. Zhifei is currently one of 5 Chinese companies conducting phase 3 clinical trials for COVID-19 vaccines in various parts of the world. Following successful Phase 3 trials, MyEG will be the sole distributor of the vaccine in Malaysia.
Several weeks ago, the Malaysian government signed an agreement to secure 12.8 million doses of the COVID-19 vaccine from Pfizer Inc, which is enough to vaccinate 6.4 million people. The first batch is expected to arrive in the first quarter of 2021 with priority for the front line.
Dr. Noor Hisham Abdullah, Director General of Health, had emphasized that all COVID-19 vaccines must obtain approval from the Ministry of Health before they can be administered. He denied the accusation that being first in line to receive COVID-19 vaccines was equivalent to test subjects, as a great deal of research and evaluation is needed before approving the use of any vaccine.
[ IMAGE SOURCE ]